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Background: Methylenedioxymethamphetamine (MDMA; ecstasy) is used recreationally and 
has been investigated as an adjunct to psychotherapy. Most acute effects of MDMA can be 
attributed to activation of the serotonin (5-hydroxytryptamine [5-HT]) system. Genetic 
variants, such as single-nucleotide polymorphisms (SNPs) and polymorphic regions in 5-HT 
system genes, may contribute to interindividual differences in the acute effects of MDMA.  
Methods: We characterized the effects of common genetic variants within selected genes that 
encode the 5-HT system (TPH1 [tryptophan 5-hydroxylase 1] rs1800532 and rs1799913, TPH2 
[tryptophan 5-hydroxylase 2] rs7305115, HTR1A [5-HT1A receptor] rs6295, HTR1B [5-HT1B 
receptor] rs6296, HTR2A [5-HT2A receptor] rs6313, and SLC6A4 [serotonin transporter] 5-
HTTLPR and rs25531) on the physiological and subjective response to 125 mg MDMA 
compared with placebo in 124 healthy subjects. Data were pooled from eight randomized, 
double-blind, placebo-controlled studies that were conducted in the same laboratory. 
Results: TPH2 rs7305115, HTR2A rs6313, and SLC6A4 5-HTTLPR polymorphisms tended to 
moderately alter some effects of MDMA. However, after correcting for multiple testing, none 
of the tested genetic polymorphisms significantly influenced the response to MDMA. 
Conclusions: Genetic variations of genes that encode key targets in the 5-HT system did not 
significantly influence the effects of MDMA in healthy subjects. Interindividual differences in 







3,4-Methylenedioxymethamphetamine (MDMA; molly, ecstasy) is popularly used for 
its empathic and euphoric effects. Recent research indicates that MDMA may also be useful as 
an adjunct to psychotherapy in patients with posttraumatic stress disorder (PTSD; 1-3. MDMA 
mainly acts as a releaser of serotonin (5-hydroxytryptamine [5-HT]) and norepinephrine and 
to a lesser extent dopamine 4, 5. Compared with amphetamine, typical effects of MDMA can be 
predominantly attributed to activation of the 5-HT system 6-16. Key components of the 5-HT 
system include tryptophan hydroxylase (TPH), the 5-HT transporter (SERT), and 5-HT1A, 5-
HT1B, and 5-HT2A receptors. Manipulations of 5-HT system targets could modulate the effects 
of MDMA. Pharmacological inhibition of the SERT significantly reduced the psychotropic and 
most physiological effects of MDMA 11, 13, 16, 17. Inhibition of the 5-HT2A receptor also 
attenuated some of the acute effects of MDMA 12, 18, 19, whereas 5HT1 receptor inhibition had 
no effect 20, 21. 
The role of the 5-HT system in the acute effects of MDMA has been well studied, but 
little is known about the ways in which interindividual variations of genes that encode targets 
that are implicated in the mechanism of action of MDMA or its metabolism influence the 
response to MDMA. For example, genetic variations of the enzymes that are involved in 
MDMA metabolism (mainly CYP2D6) have been shown to affect plasma levels of MDMA 
and its metabolites in several clinical studies 22-24 and modulate the pharmacokinetics and some 
of the pharmacodynamic effects of MDMA. Genetic variants of pharmacological targets of 
MDMA may also alter its pharmacodynamic effects, but the few studies that have been 
published to date have reported no or only minimal effects, including potential chance findings 
25-28. 
The major target of MDMA in the 5-HT system is the SERT 4, 5, 11, 29. A common repeat 
polymorphism in the promoter region of the SLC6A4 gene (5-HTTLPR), which encodes the 
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SERT, comprises two variants with long (L) and short (S) alleles. Each variant includes a 
number of SNP variants. However, in the Caucasian population, only the rs25331 SNP is 
important 30. In vitro, cells with the LL polymorphism have approximately double the uptake 
activity of cells that carry one or two copies of the S allele 31. In humans, individuals with the 
L allele and G variant of rs25331 present the same low-expressing phenotypes as S-allele 
carriers 32-34. Consequently, LG or short 5-HTTLPR allele carriers should present higher levels 
of serotonin in the synaptic cleft and thus an increase in serotonin signaling compared with 
homozygous LA carriers. However, MDMA’s efficacy crucially depends on activity of the 
SERT. Individuals with the LG or short 5-HTTLPR variant may present a reduction of 
MDMA’s effects compared with LALA carriers. Kuypers et al. (2018b) performed a study with 
63 polydrug users and found that 75 mg MDMA produced more anxiety in homozygous L 
carriers compared with the S group and acutely attenuated self-rated depression in women in 
the LL group. Pardo-Lozano et al. (2012) found higher MDMA-induced cardiovascular effects 
in L-allele carriers than in SS individuals and more sedation in the SS group than in L-allele 
carriers 35. Furthermore, regular ecstasy users who were carriers of the S allele presented a 
higher risk of mood disorders and emotional and cognitive dysfunction and performed worse 
on a verbal fluency task 36-39. Finally, MDMA produced a two-fold increase in SERT gene 
expression, and this increase tended to be more pronounced in homozygous L carriers 40. In 
contrast, no association was found between the 5-HTTLPR polymorphism and MDMA-
induced impairments in memory function or MDMA-induced changes in cortisol levels 41, 42. 
MDMA indirectly and partially also directly interacts with 5-HT receptors 5, 10, 43. 
Single-nucleotide polymorphisms of the genes that encode 5-HT receptors could influence the 
effects of MDMA, but this possibility has not yet been investigated. The rs6295 SNP of the 
HTR1A gene, which encodes the 5-HT1A receptor, may play a role in substance use disorder 
44. 
Female homozygous carriers of the G allele of the rs6295 who suffered from major depressive 
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disorder benefited more from treatment with a SERT inhibitor than carriers of the C allele 45. 
The rs6296 SNP of HTR1B, which encodes the 5-HT1B receptor, was found to influence 
childhood aggressive behavior. Individuals who were homozygous for the C-allele were more 
aggressive than those who carried the G allele 46. 5-HT2A receptors are one of the most 
researched targets of psychoactive drugs. The C allele of the rs6313 SNP of HTR2A, which 
encodes the 5-HT2A receptor, is associated with lower expression and was found to be 
associated with suicide, a lower ability to adopt the point of view of others, greater anxiety 
when observing pain, and communication problems 47-49. However, the rs6313 SNP did not 
modulate cognitive dysfunction in chronic ecstasy users 38. 
The rate-limiting step in 5-HT biosynthesis is catalyzation by TPH, and MDMA inhibits 
TPH activity 50, 51. Tryptophan hydroxylase has two isoforms: TPH1 and TPH2. The rs1800532 
SNP of TPH1 has been reported to influence gene transcription, and the rare T allele was 
associated with a decrease in 5-HT synthesis 52. The T allele has also been associated with 
SERT inhibitor treatment efficacy and the risk for bipolar disorder and alcohol dependence 53, 
54. Additionally, the rs7305115 SNP of TPH2 has been associated with susceptibility to suicide, 
in which the A allele was significantly less frequent in suicide attempters than in non-
attempters 55, 56. 
The present study investigated whether the acute effects of MDMA are influenced by 
genetic variations within the serotonergic system. We evaluated whether the TPH1 rs1800532 
and rs1799913 SNPs, TPH2 rs7305115 SNP, HTR1A rs6295 SNP, HTR1B rs6296 SNP, 
HTR2A rs6313 SNP, and SLC6A4 5-HTTLPR and rs25531 polymorphisms influence MDMA-
induced subjective, emotional, empathic, cardiovascular, thermogenic, and adverse effects. We 
expected that the results of previous smaller studies that included some of these SNPs would 





Effects of the SNPs on the maximum response (Emax) to MDMA are shown in Table 1. 
Supplementary Table S1 shows the data for the response to MDMA over time (AUEC).  
Supplementary Tables S2 and S3 show the uncorrected statistics for Emax and AUEC, 
respectively. Sex did not significantly alter the results. 
Table 1. Effects of polymorphisms in the serotonergic system on the maximal response to 125 mg MDMA (mean±SD and statistics) corrected 
with MDMA AUC6 (exclusive plasma concentrations) 
  TPH1 
rs1800532 
GG GT TT   F p value p valuea 
 N (%)  44 (35) 62 (50) 18 (15)     
 Female, N (%)  23 (52) 31 (50) 10 (56)     
 MDMA plasma concentration Cmax, 
ng/ml 
N: 44, 62, 18 221±51 228±48 232±42  0.43 NS  
 MDMA plasma concentration AUC6, 
ng*h/ml 
N: 44, 62, 18 944±221 949±202 998±200  0.48 NS  
          
Visual Analog Scale rating ΔEmax                 
 Any drug effect N: 44, 62, 18 81±19 73±26 74±26  2.32 NS NS 
 Good drug effect N: 44, 62, 18 81±23 72±29 72±28  2.00 NS NS 
 Bad drug effect N: 44, 62, 18 14±23 21±29 14±19  1.50 NS NS 
 Drug liking N: 44, 62, 18 81±21 74±29 76±29  1.05 NS NS 
 Closeness to others N: 44, 62, 18 23±17 21±19 27±19  0.39 NS NS 
 High-mood N: 44, 62, 18 74±32 71±31 71±31  0.37 NS NS 
 Talkative N: 44, 62, 18 25±20 19±19 25±17  1.38 NS NS 
 Appetite N: 24, 42, 6 -7±33 -6±31 -15±22  0.20 NS NS 
 Tired N: 41, 53, 15 21±32 18±33 23±31  0.13 NS NS 
 Fear N: 24, 42, 6 4±14 9±20 4±9  0.91 NS NS 
 Happy N: 26, 40, 15 28±18 27±20 33±18  0.29 NS NS 
 Content N: 26, 40, 15 32±14 29±21 32±18  0.65 NS NS 
 Trust N: 20, 20, 12 23±18 23±23 25±26  0.15 NS NS 
 want to be hugged N: 20, 20, 12 11±19 19±20 24±20  0.83 NS NS 
 want to hug N: 20, 20, 12 14±19 19±19 23±19  0.33 NS NS           
Vital signs parameters ΔEmax                 
 Systolic blood pressure, mmHg N: 44, 62, 18 26±12 22±13 27±12  1.62 NS NS 
 Diastolic blood pressure, mmHg N: 44, 62, 18 14±11 14±9 15±9  0.04 NS NS 
 Mean arterial pressure, mmHg N: 44, 62, 18 18±10 17±10 19±9  0.13 NS NS 
 Rate pressure product, mmHg/min N: 44, 62, 18 5311±3048 4314±2906 4779±2783  1.61 NS NS 
 Body temperature, °C N: 44, 62, 18 0.3±0.5 0.2±0.5 0.4±0.5  1.27 NS NS           
Adjective Mood Rating Scale rating ΔEmax                 
 well-being N: 44, 62, 18 5.8±5.5 4.9±5.1 4.9±6.5  0.38 NS NS 
 high mood N: 44, 62, 18 3.5±3.1 2.7±3.1 2.9±3.7  0.75 NS NS 
 fear/depression N: 44, 62, 18 0.0±3.4 1.3±3.2 0.6±2.0  2.40 NS NS 
 dreaminess N: 44, 62, 18 3.3±2.6 3.1±3.5 2.5±3.2  0.58 NS NS           
List of Complaints Δscore                 
 acute, up to 6h, N N: 44, 62, 18 8.5±7.4 8.6±6.8 8.5±4.8  0.04 NS NS 
 subacute, up to 24h, N N: 44, 62, 18 5.1±5.6 4.7±5.3 3.7±5.4  0.70 NS NS 
                    
  TPH2 
rs7305115 
AA AG GG   F p value p valuea 
 N (%)  14 (11) 61 (49) 49 (40)     
 Female, N (%)  7 (50) 30 (49) 27 (55)     
 MDMA plasma concentration Cmax, 
ng/ml 
N: 14, 61, 49 221±46 225±49 228±49  0.15 NS  
 MDMA plasma concentration AUC6, 
ng*h/ml 
N: 14, 61, 49 958±215 947±209 962±207  0.08 NS  
          
Visual Analog Scale rating ΔEmax                 
 Any drug effect N: 14, 61, 49 77±20 75±25 77±24  0.11 NS NS 
 Good drug effect N: 14, 61, 49 71±31 74±28 79±24  0.59 NS NS 
 Bad drug effect N: 14, 61, 49 17±21 15±29 20±22  0.33 NS NS 
 Drug liking N: 14, 61, 49 69±35 76±27 81±23  1.27 NS NS 
 Closeness to others N: 14, 61, 49 19±20 22±17 25±19  0.85 NS NS 
 High-mood N: 14, 61, 49 72±29 69±34 75±28  0.49 NS NS 
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 Talkative N: 14, 61, 49 18±23 21±19 24±17  0.76 NS NS 
 Appetite N: 7, 33, 32 -3±32 -9±28 -6±34  0.07 NS NS 
 Tired N: 12, 54, 43 13±34 20±31 22±33  0.28 NS NS 
 Fear N: 7, 33, 32 -1±12 6±19 9±17  0.86 NS NS 
 Happy N: 12, 41, 28 27±21 28±18 29±20  0.05 NS NS 
 Content N: 12, 41, 28 27±22 30±17 32±19  0.28 NS NS 
 Trust N: 7, 28, 17 14±30 23±20 28±21  1.11 NS NS 
 want to be hugged N: 7, 28, 17 7±8 14±20 26±20  2.29 NS NS 
 want to hug N: 7, 28, 17 7±8 16±19 26±20  2.62 NS NS           
Vital signs parameters ΔEmax                 
 Systolic blood pressure, mmHg N: 14, 61, 49 22±13 25±14 23±11  0.92 NS NS 
 Diastolic blood pressure, mmHg N: 14, 61, 49 14±9 15±10 14±8  0.28 NS NS 
 Mean arterial pressure, mmHg N: 14, 61, 49 16±10 18±10 17±9  0.50 NS NS 
 Rate pressure product, mmHg/min N: 14, 61, 49 3757±2787 4786±2838 4952±3135  0.95 NS NS 
 Body temperature, °C N: 14, 61, 49 -0.1±0.6 0.3±0.5* 0.2±0.4  4.11 0.019 NS           
Adjective Mood Rating Scale rating ΔEmax                 
 well-being N: 14, 61, 49 3.4±4.3 5.3±6.0 5.5±4.9  0.91 NS NS 
 high mood N: 14, 61, 49 2.4±3.1 3.1±3.5 3.0±3.0  0.33 NS NS 
 fear/depression N: 14, 61, 49 -0.5±3.3 0.8±3.6 1.0±2.5  1.19 NS NS 
 dreaminess N: 14, 61, 49 2.9±3.6 2.8±2.9 3.4±3.3  0.51 NS NS           
List of Complaints Δscore                 
 acute, up to 6h, N N: 14, 61, 49 7.4±7.1 8.4±6.7 9.0±6.8  0.30 NS NS 
 subacute, up to 24h, N N: 14, 61, 49 2.9±4.2 4.7±5.9 5.2±5.0  0.97 NS NS 
                    
  5HTR1A 
rs6295 
CC CG GG   F p value p valuea 
 N (%)  29 (23) 68 (55) 27 (22)     
 Female, N (%)  14 (48) 36 (53) 14 (52)     
 MDMA plasma concentration Cmax, 
ng/ml 
N: 29, 68, 27 218±46 233±48 216±50  1.64 NS  
 MDMA plasma concentration AUC6, 
ng*h/ml 
N: 29, 68, 27 903±180 1005±216# 880±183  4.99 0.008  
          
Visual Analog Scale rating ΔEmax                 
 Any drug effect N: 29, 68, 27 79±20 79±23 66±27  2.06 NS NS 
 Good drug effect N: 29, 68, 27 77±23 77±28 71±29  0.37 NS NS 
 Bad drug effect N: 29, 68, 27 25±24 17±26 10±24  2.78 NS NS 
 Drug liking N: 29, 68, 27 78±23 78±28 73±28  0.23 NS NS 
 Closeness to others N: 29, 68, 27 21±20 24±18 21±16  0.08 NS NS 
 High-mood N: 29, 68, 27 70±31 73±33 71±29  0.16 NS NS 
 Talkative N: 29, 68, 27 18±18 24±19 21±18  0.46 NS NS 
 Appetite N: 18, 38, 16 -13±37 -3±28 -10±30  1.49 NS NS 
 Tired N: 26, 58, 25 23±34 22±31 11±33  1.05 NS NS 
 Fear N: 18, 38, 16 6±9 9±23 3±8  0.79 NS NS 
 Happy N: 16, 48, 17 25±20 28±20 33±16  1.09 NS NS 
 Content N: 16, 48, 17 28±19 30±19 33±18  0.57 NS NS 
 Trust N: 11, 30, 11 20±24 23±21 27±24  1.10 NS NS 
 want to be hugged N: 11, 30, 11 14±19 18±21 19±19  0.55 NS NS 
 want to hug N: 11, 30, 11 14±19 18±20 22±16  1.23 NS NS           
Vital signs parameters ΔEmax                 
 Systolic blood pressure, mmHg N: 29, 68, 27 21±15 25±12 23±12  0.37 NS NS 
 Diastolic blood pressure, mmHg N: 29, 68, 27 16±9 14±10 13±9  0.99 NS NS 
 Mean arterial pressure, mmHg N: 29, 68, 27 18±10 18±10 16±9  0.38 NS NS 
 Rate pressure product, mmHg/min N: 29, 68, 27 4916±3052 4707±3032 4612±2729  0.39 NS NS 
 Body temperature, °C N: 29, 68, 27 0.2±0.6 0.2±0.5 0.3±0.4  0.50 NS NS           
Adjective Mood Rating Scale rating ΔEmax                 
 well-being N: 29, 68, 27 4.9±5.3 5.4±4.9 5.1±6.7  0.07 NS NS 
 high mood N: 29, 68, 27 2.6±3.2 3.0±3.0 3.4±3.9  0.42 NS NS 
 fear/depression N: 29, 68, 27 0.2±3.2 1.3±3.3 0.0±2.7  2.32 NS NS 
 dreaminess N: 29, 68, 27 3.2±3.3 3.4±3.2 2.1±2.7  1.30 NS NS           
List of Complaints Δscore                 
 acute, up to 6h, N N: 29, 68, 27 7.7±7.0 9.1±6.4 8.0±7.3  0.09 NS NS 
 subacute, up to 24h, N N: 29, 68, 27 5.7±5.0 4.5±5.8 4.1±4.8  1.22 NS NS 
                    
  5HTR1B 
rs6296 
CC CG GG   F p value p valuea 
 N (%)  69 (56) 45 (36) 10 (8)     
 Female, N (%)  34 (49) 23 (51) 7 (70)     
 MDMA plasma concentration Cmax, 
ng/ml 
N: 69, 45, 10 222±47 229±50 241±49  0.87 NS  
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 MDMA plasma concentration AUC6, 
ng*h/ml 
N: 69, 45, 10 925±203 976±208 1061±209  2.32 NS  
          
Visual Analog Scale rating ΔEmax                 
 Any drug effect N: 69, 45, 10 75±22 77±24 77±32  0.45 NS NS 
 Good drug effect N: 69, 45, 10 74±28 79±25 71±28  0.82 NS NS 
 Bad drug effect N: 69, 45, 10 18±24 16±29 19±25  0.40 NS NS 
 Drug liking N: 69, 45, 10 77±27 79±25 70±30  0.89 NS NS 
 Closeness to others N: 69, 45, 10 22±18 23±19 28±18  0.07 NS NS 
 High-mood N: 69, 45, 10 70±31 76±31 66±39  0.87 NS NS 
 Talkative N: 69, 45, 10 21±19 22±20 24±16  0.00 NS NS 
 Appetite N: 40, 27, 5 -4±31 -14±32 -2±22  0.55 NS NS 
 Tired N: 63, 39, 7 22±34 19±31 4±21  1.84 NS NS 
 Fear N: 40, 27, 5 7±19 7±16 0±17  0.41 NS NS 
 Happy N: 44, 30, 7 28±19 28±20 37±17  0.26 NS NS 
 Content N: 44, 30, 7 31±18 28±19 37±17  0.53 NS NS 
 Trust N: 29, 18, 5 20±22 23±22 45±7  1.15 NS NS 
 want to be hugged N: 29, 18, 5 14±19 19±21 26±22  0.51 NS NS 
 want to hug N: 29, 18, 5 14±18 21±19 27±21  1.18 NS NS           
Vital signs parameters ΔEmax                 
 Systolic blood pressure, mmHg N: 69, 45, 10 23±13 27±12 22±10  1.41 NS NS 
 Diastolic blood pressure, mmHg N: 69, 45, 10 14±10 13±9 16±11  0.46 NS NS 
 Mean arterial pressure, mmHg N: 69, 45, 10 18±10 18±10 17±10  0.21 NS NS 
 Rate pressure product, mmHg/min N: 69, 45, 10 4513±2801 5306±3130 3702±2956  1.91 NS NS 
 Body temperature, °C N: 69, 45, 10 0.2±0.5 0.3±0.5 0.2±0.7  0.75 NS NS           
Adjective Mood Rating Scale rating ΔEmax                 
 well-being N: 69, 45, 10 5.2±5.1 4.7±5.9 7.7±4.9  1.24 NS NS 
 high mood N: 69, 45, 10 2.9±3.1 2.7±3.3 4.7±3.2  1.57 NS NS 
 fear/depression N: 69, 45, 10 1.0±3.0 0.5±3.7 -0.2±1.9  0.82 NS NS 
 dreaminess N: 69, 45, 10 3.0±3.2 3.0±3.2 4.1±2.8  0.37 NS NS           
List of Complaints Δscore                 
 acute, up to 6h, N N: 69, 45, 10 8.2±6.8 9.4±6.5 7.0±7.5  0.90 NS NS 
 subacute, up to 24h, N N: 69, 45, 10 5.0±5.5 4.6±5.3 3.2±5.9  1.18 NS NS 
                    
  5HTR2A 
rs6313 
AA AG GG   F p value p valuea 
 N (%)  22 (18) 62 (50) 40 (32)     
 Female, N (%)  8 (36) 36 (58) 20 (50)     
 MDMA plasma concentration Cmax, 
ng/ml 
N: 22, 62, 40 211±44 238±48 216±47  4.00 0.021  
 MDMA plasma concentration AUC6, 
ng*h/ml 
N: 22, 62, 40 885±173 990±206 937±220  2.30 NS  
          
Visual Analog Scale rating ΔEmax                 
 Any drug effect N: 22, 62, 40 69±24 80±23 73±24  0.53 NS NS 
 Good drug effect N: 22, 62, 40 76±23 81±26+ 66±29  3.46 0.035 NS 
 Bad drug effect N: 22, 62, 40 13±20 17±27 22±25  1.05 NS NS 
 Drug liking N: 22, 62, 40 77±20 82±27 69±27  2.23 NS NS 
 Closeness to others N: 22, 62, 40 20±17 26±18 19±19  1.06 NS NS 
 High-mood N: 22, 62, 40 67±31 79±29 64±33  2.45 NS NS 
 Talkative N: 22, 62, 40 22±18 24±19 19±19  0.39 NS NS 
 Appetite N: 12, 42, 18 -6±29 -8±29 -6±37  0.07 NS NS 
 Tired N: 20, 54, 35 22±27 20±34 18±33  0.19 NS NS 
 Fear N: 12, 42, 18 0±4 6±13 14±27  2.72 NS NS 
 Happy N: 17, 34, 30 29±17 32±18 24±21  0.94 NS NS 
 Content N: 17, 34, 30 32±17 32±19 27±19  0.52 NS NS 
 Trust N: 10, 20, 22 35±17+ 28±20 14±23  3.62 0.034 NS 
 want to be hugged N: 10, 20, 22 17±19 23±20 12±20  1.07 NS NS 
 want to hug N: 10, 20, 22 20±17 23±19 12±20  1.09 NS NS           
Vital signs parameters ΔEmax                 
 Systolic blood pressure, mmHg N: 22, 62, 40 21±10 25±14 24±12  0.42 NS NS 
 Diastolic blood pressure, mmHg N: 22, 62, 40 14±14 14±9 14±7  0.17 NS NS 
 Mean arterial pressure, mmHg N: 22, 62, 40 17±12 18±10 18±8  0.02 NS NS 
 Rate pressure product, mmHg/min N: 22, 62, 40 4522±2610 4439±2772 5311±3360  1.61 NS NS 
 Body temperature, °C N: 22, 62, 40 0.3±0.5 0.2±0.6 0.2±0.5  0.21 NS NS           
Adjective Mood Rating Scale rating ΔEmax                 
 well-being N: 22, 62, 40 5.1±4.1 6.3±5.1+ 3.5±6.1  3.18 0.045 NS 
 high mood N: 22, 62, 40 2.8±2.7 3.7±3.0++ 2.0±3.6  3.78 0.026 NS 
 fear/depression N: 22, 62, 40 0.9±2.9 0.5±3.1 1.1±3.6  0.52 NS NS 
 dreaminess N: 22, 62, 40 2.9±3.8 3.9±3.0+ 2.0±2.7  4.02 0.020 NS           
List of Complaints Δscore                 
 acute, up to 6h, N N: 22, 62, 40 7.3±5.8 8.2±6.6 9.8±7.4  1.27 NS NS 
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 subacute, up to 24h, N N: 22, 62, 40 3.9±5.4 4.6±5.0 5.3±6.1  0.57 NS NS 
                    
  SLC6A4 5-
HTTPLR 
LL LS SS   F p value p valuea 
 N (%)  45 (36) 60 (48) 19 (15)     
 Female, N (%)  27 (60) 26 (43) 11 (58)     
 MDMA plasma concentration Cmax, 
ng/ml 
N: 45, 60, 19 232±50 222±44 223±57  0.61 NS  
 MDMA plasma concentration AUC6, 
ng*h/ml 
N: 45, 60, 19 1000±222 933±187 913±224  1.80 NS  
          
Visual Analog Scale rating ΔEmax                 
 Any drug effect N: 45, 60, 19 74±24 77±24 77±22  2.17 NS NS 
 Good drug effect N: 45, 60, 19 70±27 77±26 83±29  3.67 0.028 NS 
 Bad drug effect N: 45, 60, 19 25±25 13±27 13±17  2.46 NS NS 
 Drug liking N: 45, 60, 19 72±27 79±25 83±31  2.79 NS NS 
 Closeness to others N: 45, 60, 19 19±20 24±17 26±18  3.07 NS NS 
 High-mood N: 45, 60, 19 68±32 72±32 81±26  2.47 NS NS 
 Talkative N: 45, 60, 19 22±18 21±19 23±19  0.24 NS NS 
 Appetite N: 20, 41, 11 -8±31 -7±32 -8±30  0.10 NS NS 
 Tired N: 39, 54, 16 26±31 19±33 8±31  1.27 NS NS 
 Fear N: 20, 41, 11 11±17 6±19 2±6  1.00 NS NS 
 Happy N: 33, 36, 12 26±21 29±17 32±20  1.17 NS NS 
 Content N: 33, 36, 12 28±19 31±17 33±20  0.84 NS NS 
 Trust N: 25, 19, 8 23±23 24±21 24±21  0.35 NS NS 
 want to be hugged N: 25, 19, 8 17±21 18±20 18±19  0.26 NS NS 
 want to hug N: 25, 19, 8 18±20 17±19 20±18  0.15 NS NS           
Vital signs parameters ΔEmax                 
 Systolic blood pressure, mmHg N: 45, 60, 19 23±13 25±13 24±11  0.97 NS NS 
 Diastolic blood pressure, mmHg N: 45, 60, 19 15±11 13±9 15±9  0.44 NS NS 
 Mean arterial pressure, mmHg N: 45, 60, 19 18±11 18±9 18±8  0.21 NS NS 
 Rate pressure product, mmHg/min N: 45, 60, 19 4525±2971 4799±3031 5031±2764  0.63 NS NS 
 Body temperature, °C N: 45, 60, 19 0.1±0.5 0.3±0.6 0.3±0.4  1.11 NS NS           
Adjective Mood Rating Scale rating ΔEmax                 
 well-being N: 45, 60, 19 5.4±5.0 4.4±5.4 7.2±5.9  1.93 NS NS 
 high mood N: 45, 60, 19 3.2±3.1 2.5±3.3 4.2±3.1  2.23 NS NS 
 fear/depression N: 45, 60, 19 1.6±3.0 0.1±3.4 0.6±2.7  3.07 NS NS 
 dreaminess N: 45, 60, 19 3.0±3.2 3.1±3.2 3.1±3.2  0.10 NS NS           
List of Complaints Δscore                 
 acute, up to 6h, N N: 45, 60, 19 9.7±7.1 7.4±6.8 9.4±5.3  1.28 NS NS 
 subacute, up to 24h, N N: 45, 60, 19 5.3±5.9 4.8±5.2 2.9±4.8  0.97 NS NS 
                    





  F p value p valuea 
 N (%)  42 (34) 56 (46) 25 (20)     
 Female, N (%)  25 (60) 24 (43) 15 (60)     
 MDMA plasma concentration Cmax, 
ng/ml 
N: 42, 56, 25 233±51 220±44 230±54  0.97 NS  
 MDMA plasma concentration AUC6, 
ng*h/ml 
N: 42, 56, 25 998±225 931±189 945±217  1.32 NS  
          
Visual Analog Scale rating ΔEmax                 
 Any drug effect N: 42, 56, 25 74±26 76±24 82±21  2.52 NS NS 
 Good drug effect N: 42, 56, 25 70±28 76±25 85±26  3.69 0.028 NS 
 Bad drug effect N: 42, 56, 25 24±24 13±28 17±21  1.32 NS NS 
 Drug liking N: 42, 56, 25 72±28 78±24 84±29  2.69 NS NS 
 Closeness to others N: 42, 56, 25 20±20 22±17 28±17  2.74 NS NS 
 High-mood N: 42, 56, 25 67±34 71±31 84±24  3.44 0.035 NS 
 Talkative N: 42, 56, 25 23±19 20±19 24±18  0.30 NS NS 
 Appetite N: 20, 35, 17 -7±30 -6±31 -9±32  0.13 NS NS 
 Tired N: 37, 49, 22 26±31 19±33 12±33  0.97 NS NS 
 Fear N: 20, 35, 17 10±17 5±20 6±11  0.56 NS NS 
 Happy N: 30, 38, 12 26±21 30±17 32±20  1.13 NS NS 
 Content N: 30, 38, 12 28±19 32±17 33±20  0.97 NS NS 
 Trust N: 22, 21, 8 22±23 26±21 24±21  0.43 NS NS 
 want to be hugged N: 22, 21, 8 16±20 18±21 18±19  0.18 NS NS 
 want to hug N: 22, 21, 8 17±19 18±20 20±18  0.13 NS NS           
Vital signs parameters ΔEmax                 
 Systolic blood pressure, mmHg N: 42, 56, 25 22±13 25±13 26±11  1.81 NS NS 
 Diastolic blood pressure, mmHg N: 42, 56, 25 15±11 13±9 16±8  1.03 NS NS 
 Mean arterial pressure, mmHg N: 42, 56, 25 17±11 17±9 20±8  0.84 NS NS 
 Rate pressure product, mmHg/min N: 42, 56, 25 4503±2954 4539±2959 5622±2880  1.66 NS NS 
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 Body temperature, °C N: 42, 56, 25 0.2±0.5 0.2±0.6 0.4±0.4  0.89 NS NS           
Adjective Mood Rating Scale rating ΔEmax                 
 well-being N: 42, 56, 25 5.1±4.9 4.6±5.7 6.4±5.5  0.90 NS NS 
 high mood N: 42, 56, 25 3.0±3.1 2.5±3.4 3.8±3.0  1.25 NS NS 
 fear/depression N: 42, 56, 25 1.6±2.8 0.3±3.3 0.3±3.5  2.33 NS NS 
 dreaminess N: 42, 56, 25 3.1±3.2 3.0±3.1 3.3±3.2  0.08 NS NS           
List of Complaints Δscore                 
 acute, up to 6h, N N: 42, 56, 25 9.2±7.2 7.9±6.7 9.1±6.2  0.28 NS NS 
 subacute, up to 24h, N N: 42, 56, 25 5.2±5.9 4.7±5.2 4.0±5.3  0.22 NS NS 
                    
N, number of subjects; SD, standard deviation; NS, not significant; D, values are change scores from placebo; ap value additionally corrected 
for multiple comparisons according to the Nyholt method; * p < 0.05 compared to AA; # p < 0.05; + p < 0.05, ++ p < 0.01 compared to GG. 
 
Genotyping 
The distribution of the alleles and genotypes did not differ from the distributions that 
were reported elsewhere in Caucasian cohorts (Ensembl database release 94, October 2018). 
The minor allele frequencies for rs1800532 and rs1799913, rs7305115, rs6295, rs6296, rs6313, 
5-HTTLPR, and rs25531 were T (98 [40%]), A (89 [36%]), G (122 [49%]), G (65 [26%]), A 
(106 [43%]), S (98 [40%]), and LG+S (106 [43%]) respectively. The tested genetic variants 
were consistent with Hardy-Weinberg equilibrium (p > 0.05). 
 
Subjective effects 
 On the tested VASs and AMRSs, MDMA significantly altered the Emax values for all 
reported parameters. With the exception of a decrease in “appetite,” all of the parameters were 
increased by MDMA (Fig 1). The effects of serotonergic system gene polymorphisms on the 
subjective effects of MDMA are shown in Table 1. Carriers of the HTR2A rs6313 A allele had 
higher ratings of “good drug effect,” “trust,” AMRS “well-being,” “high-mood,” and 
“dreaminess” compared with homozygous G-allele carriers (F1,121 = 6.93, p < 0.01, F1,49 = 6.07, 
p < 0.05, F1,121 = 5.68, p < 0.05, F1,121 = 6.04, p < 0.05, and F1,121 = 6.95, p < 0.01, respectively). 
Individuals with the short allele of 5-HTTLPR had higher ratings of “good drug effect,” “drug 
liking,” and “closeness to others” and lower ratings of “bad drug effect” compared with the 
homozygous long allele group (F1,121 = 6.51, p < 0.05, F1,121 = 5.06, p < 0.05, F1,121 = 5.95, p 
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< 0.05, and F1,121 = 4.94, p < 0.05, respectively). Subjects with two long alleles had higher 
ratings of “fear and depression” on the AMRS compared with short allele carriers (F1,121 = 
5.78, p < 0.05). Subjects with the LALA genotype of the SLC6A4 rs25331 SNP had higher 
ratings of “fear and depression” on the AMRS and lower ratings of “any drug effect,” “good 
drug effect,” and “drug liking” compared with short allele and LG carriers (F1,120 = 4.70, p < 
0.05, F1,120 = 4.00, p < 0.05, F1,120 = 5.48, p < 0.05, and F1,120 = 4.51, p < 0.05, respectively). 
Nyholt correction for multiple comparisons indicated that the genetic polymorphisms had no 
significant effect on these subjective parameters. 
 
 
Figure 1. Maximal effects of MDMA on subjective Visual Analog Scale ratings. MDMA 
significantly altered Emax values for all of the reported parameters. With the exception of a 
decrease in “appetite,” all of the parameters were increased by MDMA. The data are expressed 






On the FERT, MDMA impaired the recognition of fearful, sad, and angry faces 
compared with placebo (F1,67 = 47, p < 0.001, F1,67 = 15, p < 0.001, and F1,67 = 17, p < 0.001, 
respectively). None of the serotonergic system gene variants modulated the effects of MDMA 
on the FERT. 
 
Empathy 
 MDMA decreased cognitive empathy for all emotions (F1,67 = 5.0, p < 0.05) and 
increased explicit emotional empathy for positive emotions (F1,67 = 8.5, p < 0.01) compared 




MDMA significantly increased the Emax values for blood pressure, MAP, RPP, and 
body temperature. The effects of the polymorphisms on elevations of blood pressure, MAP, 
RPP, and body temperature in response to MDMA are shown in Table 1. MDMA produced a 
higher peak body temperature in G-allele carriers of the TPH2 rs7305115 SNP compared with 
homozygous A-allele carriers (F1,121 = 4.84, p < 0.05). Nyholt correction for multiple 
comparisons indicated that the genetic polymorphisms had no significant effect on these 
physiological parameters. 
 
Adverse effects of MDMA 
MDMA significantly increased LC scores after up to 6 h and up to 24 h (Table 1). 
Specifically, MDMA increased the acute and subacute scores for “lack of appetite,” “nausea,” 
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and “dizziness.” Individuals with the GG genotype of the TPH2 rs7305115 SNP suffered more 
often from acute “lack of appetite” than individuals with the AA genotype (mean ± SD: 0.36 ± 
0.50 for AA vs. 0.76 ± 0.43 for GG; p = 0.017). Subjects with the A allele of the HTR2A rs6313 
SNP felt less acute “dizziness” than subjects who were homozygous for the G allele (mean ± 
SD: 0.25 ± 0.44 for AA/AG vs. 0.55 ± 0.55 for GG; p = 0.0012). Nyholt correction for multiple 
comparisons indicated that the genetic polymorphisms had no significant effect on the adverse 
effects of MDMA. 
 
Plasma concentrations of MDMA 
 MDMA concentrations are shown in Table 1. MDMA concentrations similarly 
increased across all serotonergic system gene variants (Table 1), with the exception of the 
rs6295 SNP (MDMA AUC6; CG vs. GG, p < 0.05) and rs6313 SNP (MDMA Cmax). Peak 
MDMA concentrations and AUC6 values were (mean ± SD) 226 ± 48 ng/ml and 954 ± 208 
ng×h/ml in the total of 124 subjects. 
 
Discussion 
 The present study investigated the effects of interindividual differences in genes that 
encode the 5-HT system on MDMA-induced mood, empathogenic, cardiovascular, 
thermogenic, and adverse effects. Although genetic variants of 5-HT system genes have been 
implicated in different phenotypes and although the effects of MDMA largely depend on the 
release of 5-HT, only the TPH2 rs7305115, HTR2A rs6313, and SLC6A4 5-HTTLPR 
polymorphisms tended to moderately alter some effects of MDMA. However, the effect size 
was limited. After applying Nyholt correction to correct for Type I errors, none of the genetic 
variants that were evaluated herein significantly influenced the acute subjective or 
physiological effects of MDMA. 
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Most of the polymorphisms that were tested in the present study were investigated for 
the first time in association with the acute effects of controlled administration of MDMA in 
healthy human subjects. We could not reproduce results from two previous smaller studies on 
the modulatory role of SLC6A4 polymorphisms in the acute effects of MDMA. One reason for 
this could be the correction for multiple testing. In fact, before correcting for multiple testing, 
our results were consistent with the findings of Kuypers et al. (2018b), which were not 
corrected for multiple testing to avoid Type II errors. In both studies, homozygous carriers of 
the L allele felt more anxiety/fear compared with S-allele carriers. However, the exploratory 
nature of the present study requires a correction method to avoid Type I errors. 
Another previous study also suggested that the 5-HTTLPR polymorphism may play an 
important role in modulating the risk of adverse effects of MDMA, mainly cardiovascular 
effects 35. However, MDMA-induced cardiovascular effects were not influenced by 5-HT 
system gene variations in the present study, which was larger and more methodologically sound 
than Pardo-Lozano et al. (2012). 
The discrepancies between these studies may be attributable to the different doses of 
MDMA. In contrast to the 75-100 mg doses of MDMA that were used in Kuypers et al. (2018b) 
and Pardo-Lozano et al. (2012), we used 125 mg MDMA, which is the dose that is also used 
in patients 1-3, 57, 58. As shown in an earlier study, the 125 mg dose is stronger and produced 
greater good drug effects compared with the 75 mg dose 59. 5-HT system genotypes may 
present more modulatory effects when MDMA is taken at a lower dose and not at higher doses, 
such as in therapeutic settings. 
The present study has limitations. First, although this is the largest uniform cohort with 
mostly MDMA-naive healthy subjects, confirmation in studies with larger samples is needed, 
which is the case for all such genetic studies. The sample size was relatively small when 
considering the mostly small effect sizes for the influence of genetic variants on the MDMA 
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response. Additionally, tests for empathy and emotion recognition were only completed by 69 
subjects. However, we unlikely missed very large effect sizes for the influence of the tested 
genetic variants. Second, the study was conducted in mostly young and healthy volunteers. 
Therefore, the findings cannot necessarily be generalized to other populations, such as 
psychiatric patients and elderly subjects. Third, SNPs of genes of other targets of MDMA may 
also be involved but were not tested in the present study. However, we corrected for the 
modulatory effects of known genetic variants that influence the metabolism of MDMA 22, 23 
and also unequal proportions of MDMA concentrations between 5-HT genotypes by 
accounting for interindividual differences in plasma MDMA concentrations. 
In light of recent efforts to use MDMA as an adjunct to psychotherapy for PTSD, 
modulators of the effects of MDMA should be identified. Our results showed that genetic 
variations of genes that encode the 5-HT system did not markedly influence the effects of 
MDMA in healthy subjects. Therefore, interactions between MDMA and 5-HT system 





 This was a pooled analysis of eight double-blind, placebo-controlled, crossover studies 
in healthy subjects that used similar methods 6, 14, 60-65. The studies included a total of 136 
healthy subjects. Seven studies included 16 subjects each, for a total of 112 subjects, who 
received 125 mg MDMA twice, once alone and once after pretreatment with a medication 6, 14, 
60-65. An additional study included 24 subjects who received 125 mg MDMA alone, placebo, 
or other treatments 6. In the present analysis, only data from the MDMA-alone and placebo 
sessions were used. In all of the studies, the washout periods between single-dose 
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administrations of MDMA were at least 7 days to exclude possible carry-over effects. The 
studies were all registered at ClinicalTrials.gov (NCT00886886, NCT00990067, 
NCT01136278, NCT01270672, NCT01386177, NCT01465685, NCT01771874, and 
NCT01951508). All of the studies were approved by the local ethics committee and Swiss 
Agency for Therapeutic Products (Swissmedic). The studies were conducted in accordance 
with the Declaration of Helsinki. MDMA administration in healthy subjects was authorized by 
the Swiss Federal Office for Public Health (BAG), Bern, Switzerland. Informed consent was 
obtained from all of the participants. All of the subjects were paid for their participation. 
Detailed pharmacokinetic and safety data from these studies have been reported elsewhere 22, 
23, 59. Test sessions were conducted in a quiet hospital research ward with no more than two 
research subjects present per session. The participants were comfortably lying in hospital beds 
and were mostly listening to music and not engaging in physical activities. MDMA was given 
without food in the fasting state in the morning at 8:00-9:00 AM. A small standardized lunch 
was served at 12:00-1:00 PM. 
 
Subjects 
 A total of 136 healthy subjects of European descent, 18-44 years old (mean ± SD = 24.8 
± 4 years), were recruited from the University of Basel campus and participated in the study. 
One genotyping sample was missing, three participants did not give consent for genotyping, 
and eight subjects participated twice (only participation that included all outcome measures 
was used), resulting in a final dataset from 124 subjects (64 women). The mean ± SD body 
weight was 68 ± 10 kg (range: 46-90 kg). 
The exclusion criteria included a history of psychiatric disorders, physical illness, a 
lifetime history of illicit drug use more than five times (with the exception of past cannabis 
use), illicit drug use within the past 2 months, and illicit drug use during the study, determined 
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by urine tests that were conducted before the test sessions as reported in detail elsewhere 14, 61-
63. Forty-two subjects had prior illicit drug experiences (1-5 times), of which 22 subjects had 
previously used MDMA (1-3 times), seven subjects had previously used amphetamine or 
methamphetamine (1 time), 10 subjects had previously used cocaine (1-3 times), six subjects 
had previously used lysergic acid diethylamide (1 time), and 11 subjects had previously used 
psilocybin (1-4 times). 
 
Study drug 
 (±)MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was administered 
orally in a single dose of 125 mg, prepared as gelatin capsules (Bichsel Laboratories, 
Interlaken, Switzerland). Similar amounts of MDMA are found in ecstasy pills 66 and have 
been used in clinical studies in patients 1, 2. The doses were not adjusted for body weight or sex. 
The dose per body weight (mean ± SD) was 1.9 ± 0.3 mg/kg (1.7 ± 0.2 mg/kg for men and 2.1 
± 0.3 mg/kg for women, range: 1.4-2.7 mg/kg). 
 
Physiological effects 
Blood pressure, heart rate, and body temperature were assessed repeatedly before and 
0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA or placebo administration. Systolic 
and diastolic blood pressure and heart rate were measured using an automatic oscillometric 
device (OMRON Healthcare Europe NA, Hoofddorp, Netherlands). The measurements were 
performed in duplicate at an interval of 1 min and after a resting time of at least 10 min. The 
averages were calculated for the analysis. Mean arterial pressure (MAP) was calculated as 
diastolic blood pressure + (systolic blood pressure – diastolic blood pressure) / 3. The rate 
pressure product (RPP) was calculated as systolic blood pressure  heart rate. Core (tympanic) 
temperature was measured using a Genius 2 ear thermometer (Tyco Healthcare Group LP, 
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Watertown, NY, USA). In one study (n = 21), the 2 h time point was not used. 
Acute and subacute adverse effects were assessed using the list of complaints (LC; 62, 
67. The scale consisted of 66 items, yielding a total adverse effects score (non-weighted sum of 
the item answers) that reliably measures physical and general discomfort. Additionally, 
serotonin-related adverse effects, such as “dizziness,” “nausea,” and “lack of appetite,” were 
analyzed separately. Bruxism (item 66, a common side effect of MDMA) was included in the 
LC that was used in 92 subjects. The LC was administered 3-6 h (acute adverse effects up to 6 
h) and 24 h (subacute adverse effects up to 24 h) after MDMA or placebo administration.  
 
Subjective effects 
 To assess subjective effects, a Visual Analog Scale (VAS) was presented as a 100 mm 
horizontal line (0-100%), marked from “not at all” on the left to “extremely” on the right. The 
VASs for “closeness to others,” “happy,” “content,” “trust,” “want to be hugged,” and “want 
to hug,” were bidirectional (±50%). “Trust,” “want to be hugged,” “want to hug,” “want to be 
alone,” and ”want to be with others,” were assessed in 52 subjects. “Appetite,” and “fear,” were 
assessed in 72 subjects. “Happy,” and “content,” were assessed in 81 subjects. “Tired” was 
assessed in 109 subjects 7. The scale was administered before and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 
3, 4, 5, and 6 h after MDMA or placebo administration. The 60-item Adjective Mood Rating 
Scale (AMRS; 68 was administered 1 h before and 1.25, 2, and 5 h after drug administration. 
 
Emotion recognition 
 To measure emotion recognition, we used the Facial Emotion Recognition Task 
(FERT), which is sensitive to the effects of MDMA 6, 8, 64, 69, 70 and other serotonergic 
substances 71. The task included 10 neutral faces and 160 faces that expressed one of four basic 
emotions (happiness, sadness, anger, and fear), with pictures morphed between 0% (neutral) 
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and 100% in 10% steps. Two female and two male pictures were used for each of the four 
emotions. The stimuli were presented in random order for 500 ms and then were replaced by 
the rating screen where the participants had to indicate the correct emotion. The outcome 
measure was accuracy (proportion correct) and misclassification (emotions that were indicated 
incorrectly). The FERT was performed 90 min after drug administration. FERT data were 
available from 68 subjects. 
 
Empathy 
 The Multifaceted Empathy Test (MET) is a reliable and valid task that assesses the 
cognitive and emotional aspects of empathy 72. The MET is sensitive to oxytocin 73, MDMA 7, 
8, 20, 74, and other psychoactive substances 71, 75. The computer-assisted test consisted of 40 
photographs that showed people in emotionally charged situations. To assess cognitive 
empathy, the participants were required to infer the mental state of the subject in each scene 
and indicate the correct mental state from a list of four responses. Cognitive empathy was 
defined as the percentage of correct responses relative to total responses. To measure emotional 
empathy, the subjects were asked to rate how much they were feeling for an individual in each 
scene (i.e., explicit emotional empathy) and how much they were aroused by each scene (i.e., 
implicit emotional empathy) on a 1-9 point scale. The latter rating provides an inherent 
additional assessment of emotional empathy, which is considered to reduce the likelihood of 
socially desirable answers. The three aspects of empathy were each tested with 20 stimuli with 
positive valence and 20 stimuli with negative valence, resulting in a total of 120 trials. The 
MET was performed 90-180 min after drug administration. MET data were available from 68 
subjects. 
 
Plasma concentrations of MDMA 
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 Plasma levels of MDMA were determined before and 0.5, 1, 1.5, 2, 3, 4, and 6 h after 
drug administration 64. 
 
Genotyping 
Genomic DNA was extracted from whole blood using the QIAamp DNA Blood Mini 
Kit (Qiagen, Hombrechtikon, Switzerland) and automated QIAcube system. Genotyping was 
performed using commercial TaqMan SNP genotyping assays (LuBio Science, Lucerne, 
Switzerland) and TaqMan Genotyping Master Mix. Fluorescence was detected using the ViiA7 
real-time polymerase chain reaction (PCR) system. We assayed the following SNPs: TPH1 
rs1800532 (assay: C___8940793_10) and rs1799913 (assay: C___2645661_10), TPH2 
rs7305115 (assay: C___8376164_10), HTR1A rs6295 (assay: C__11904666_10), HTR1B 
rs6296 (C___2523534_20), and HTR2A rs6313 (assay: C___3042197_1_). We also used the 
following method to genotype the SLC6A4 5-HTTLPR polymorphism (43 base pair [bp] 
deletion) and rs25531 SNP. Genotypes were determined by PCR using 0.025 units of 
PrimeSTAR GXL DNA polymerase (TakaraClontech), PrimeSTAR GXL buffer (1 mM Mg2+), 
dNTP Mix (2.5 mM each), and primer set 5’-GCCAGCACCTAACCCCTAAT and 5’-
GGTTGCAGGGGAGATCCT (7.5 pmol each) in a total reaction volume of 25 µl. The 
following temperature profile was applied in a T100 thermal cycler (Bio-Rad, Cressier, 
Switzerland): initial activation step of 98°C (5 min) and 45 cycles of 98°C (10 s), 60°C (15 s), 
and 68°C (30 s), with final extension at 68°C (5 min). The sizes of the resulting PCR products 
were assessed by 4% agarose gel electrophoresis. Amplicons of 212 bp were designated as 
short variant (S), and amplicons of 268 bp were designated as long variant (L). The genotypes 
of the rs25331 SNP were determined by PCR using 0.5 units of Taq DNA polymerase, 
recombinant (Thermo Fisher Scientific), 10 PCR Buffer (1 mM Mg2+), dNTP Mix (0.2 mM 
each), and the primer set 5’-GGACCGCAAGGTGGGCGGGAGGCTTGGAG and 5’-
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CTCCTAGGATCGCTCCTGCATC (0.2 pmol each) in a total volume of 25 µl. Polymerase 
chain reaction was performed with an initial activation step of 95°C (3 min) and 49 cycles of 
95°C (30 s), 59.7°C (25 s), and 72°C (30 s), with final extension at 72°C (5 min). The PCR 
products were digested using 10 units of BcnI (NciI, Thermo Fisher Scientific) and the Buffer 
Tango by incubation overnight at 37°C using the T100 thermal cycler. The sizes of the resulting 
fragments were assessed by 3% agarose gel electrophoresis. Long fragments that carried the A 
allele (244 bp) were distinguished from fragments that carried the G allele (174 bp), and the 
short PCR products resulted in a fragment size of 201 bp. The genotypes were designated as 
LALA (244 bp), LALG (244 bp + 174 bp), LGLG (174 bp), LAS (244 bp + 201 bp), LGS (201 
bp + 174 bp), and SS (201 bp). The rs25531 genotype could not be determined in one subject. 
The LG and S alleles should express an identical phenotype 32-34. Accordingly, three groups 
were defined:  group 1 (LGLG, LGS, and SS) vs. group 2 (LALG, and LAS) vs. group 3 
(LALA). The genotypes of TPH1 rs1800532 and rs1799913 were in total linkage 
disequilibrium; therefore, only the results for rs1800532 are reported. 
 
Statistical analysis 
 The statistical analyses were performed using Statistica 12 software (StatSoft, Tulsa, 
OK, USA). For repeatedly measured data, peak effects (Emax) and areas under the effect-time 
curve (AUEC) from 0-6 h values were determined for MDMA and placebo. Differences in Emax 
and AUEC values (Δ; MDMA-placebo) were then analyzed using one-way analysis of variance 
(ANOVA), with genotype as the between-group factor, followed by the Tukey post hoc test. 
To ensure that modulatory effects of genotype over time were not missed, ΔAUEC values were 
tested accordingly in an additional analysis. The level of significance was set at p < 0.05. The 
Nyholt correction method was used to account for multiple comparisons and displayed 
separately in all tables 76. We thereby corrected for the 19 subjective effects (VAS+AMRS), 3 
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emotions in the FERT and 2 empathies in the MET, 5 vital parameters, and 8 items in the LC 
which have all been shown sensitive to the effects of MDMA. In addition, this was then 
corrected for each of the 7 polymorphisms tested, resulting in 19+5+5+8 × 7 = 259 variables 
and an effective number of independent variables (Veff) of 217.48 according to Nyholt. 
Consequently, this leads to a corrected significance threshold of p < 0.00023 to keep Type I 
error rate at 5%. To account for differences in plasma concentrations of MDMA that were 
caused by differences in body weight, dosing, or metabolizing enzymes 22, 23, the area under 
the MDMA plasma concentration-time curve from 0-6 h (AUC) was included as a covariate in 
the ANOVAs, and we report the corrected statistics. Additionally, modulatory effects of sex 
were explored by adding sex as a between-subjects factor in the ANOVAs (sex × genotype). 
Emax values were obtained directly from the observed data, and the AUC and AUEC were 
calculated using the linear-log trapezoidal method in Phoenix WinNonlin 6.4 (Certara, 
Princeton, NJ, USA). The primary analysis was performed using an additive genotype model 
for SNPs. Recessive or dominant model analysis was also performed, the results of which are 
reported only when the additive model was significant. 
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Supplementary Table S1. Effects of polymorphisms in the serotonergic system on the response to 125mg MDMA (mean±SD and statistics) corrected with MDMA AUC6
Visual Analog Scale rating ΔAUEC6 TPH1 rs1800532 GG GT TT F p value p value
a TPH2 rs7305115 AA AG GG F p value p value
a 5HTR1A rs6295 CC CG GG F p value p value
a 5HTR1B rs6296 CC CG GG F p value p value
a 5HTR2A rs6313 AA AG GG F p value p value
a SLC6A4 5-HTTLPR LL
Any drug effect N: 44, 62, 18 203±91 189±99 197±84 0.59 NS NS N: 14, 61, 49 205±75 192±99 197±92 0.09 NS NS N: 29, 68, 27 193±81 208±99 165±87 0.54 NS NS N: 69, 45, 10 190±92 199±98 214±88 0.07 NS NS N: 22, 62, 40 184±90 214±95 173±89 1.60 NS NS N: 45, 60, 19 210±107
Good drug effect N: 44, 62, 18 240±118 218±119 207±106 1.17 NS NS N: 14, 61, 49 218±107 230±128 221±106 0.20 NS NS N: 29, 68, 27 217±106 237±124 202±107 0.10 NS NS N: 69, 45, 10 218±119 232±119 232±95 0.10 NS NS N: 22, 62, 40 219±119 248±112 191±117 2.32 NS NS N: 45, 60, 19 223±124
Bad drug effect N: 44, 62, 18 15±46 23±46 16±28 0.65 NS NS N: 14, 61, 49 21±31 16±54 22±31 0.22 NS NS N: 29, 68, 27 27±38 23±41 3±53 2.18 NS NS N: 69, 45, 10 19±45 18±38 30±59 0.18 NS NS N: 22, 62, 40 17±46 19±41 20±48 0.07 NS NS N: 45, 60, 19 33±60
Drug liking N: 44, 62, 18 257±118 231±119 232±132 0.99 NS NS N: 14, 61, 49 228±116 249±131 234±108 0.46 NS NS N: 29, 68, 27 230±111 248±125 232±119 0.06 NS NS N: 69, 45, 10 234±123 253±120 226±100 0.63 NS NS N: 22, 62, 40 232±121 266±111 205±125 2.65 NS NS N: 45, 60, 19 239±130
Closeness to others N: 44, 62, 18 38±59 33±59 63±68 1.43 NS NS N: 14, 61, 49 18±65 36±61 48±58 1.53 NS NS N: 29, 68, 27 36±61 39±68 41±39 0.52 NS NS N: 69, 45, 10 40±63 41±57 22±61 1.20 NS NS N: 22, 62, 40 33±58 47±62 29±60 0.64 NS NS N: 45, 60, 19 40±69
High-mood N: 44, 62, 18 180±123 170±107 168±117 0.29 NS NS N: 14, 61, 49 167±103 170±123 178±105 0.07 NS NS N: 29, 68, 27 161±100 186±124 153±96 0.09 NS NS N: 69, 45, 10 173±117 176±110 159±113 0.64 NS NS N: 22, 62, 40 161±121 192±107 151±116 1.07 NS NS N: 45, 60, 19 186±126
Talkative N: 44, 62, 18 29±70 7±71 45±100 2.11 NS NS N: 14, 61, 49 3±87 17±81 29±67 0.72 NS NS N: 29, 68, 27 3±76 24±81 31±63 1.02 NS NS N: 69, 45, 10 23±78 24±65 -11±105 1.18 NS NS N: 22, 62, 40 25±73 19±79 20±74 0.12 NS NS N: 45, 60, 19 27±87
Appetite N: 24, 42, 6 -44±94 -10±75 -33±59 1.21 NS NS N: 7, 33, 32 6±66 -28±91 -25±74 0.47 NS NS N: 18, 38, 16 -31±80 -11±79 -43±88 1.64 NS NS N: 40, 27, 5 -8±54 -43±109 -40±75 1.25 NS NS N: 12, 42, 18 -23±54 -30±81 -7±97 0.59 NS NS N: 20, 41, 11 -15±82
Tired N: 41, 53, 15 29±100 35±85 20±69 0.36 NS NS N: 12, 54, 43 39±77 28±90 31±92 0.11 NS NS N: 26, 58, 25 41±90 41±85 -5±91 2.15 NS NS N: 63, 39, 7 36±81 28±103 0±73 1.12 NS NS N: 20, 54, 35 32±55 34±94 26±97 0.10 NS NS N: 39, 54, 16 36±90
Fear N: 24, 42, 6 3±12 10±33 1±2 0.61 NS NS N: 7, 33, 32 0±4 9±37 7±13 0.28 NS NS N: 18, 38, 16 3±5 11±36 1±3 1.25 NS NS N: 40, 27, 5 7±34 7±14 1±8 0.12 NS NS N: 12, 42, 18 -1±3 4±9 18±50 2.46 NS NS N: 20, 41, 11 9±16
Happy N: 26, 40, 15 61±62 56±86 77±57 0.33 NS NS N: 12, 41, 28 48±88 62±79 66±62 0.26 NS NS N: 16, 48, 17 62±85 59±80 68±42 0.48 NS NS N: 44, 30, 7 56±80 62±68 91±61 0.30 NS NS N: 17, 34, 30 68±71 74±64 44±85 1.10 NS NS N: 33, 36, 12 58±84
Content N: 26, 40, 15 70±60 67±90 73±48 0.14 NS NS N: 12, 41, 28 57±98 71±76 72±61 0.22 NS NS N: 16, 48, 17 73±90 65±78 76±43 0.75 NS NS N: 44, 30, 7 63±80 69±66 107±62 0.51 NS NS N: 17, 34, 30 73±75 85±64 49±82 1.56 NS NS N: 33, 36, 12 67±83
Trust N: 20, 20, 12 50±59 54±85 68±71 0.04 NS NS N: 7, 28, 17 18±95 56±68 71±65 1.58 NS NS N: 11, 30, 11 40±94 55±64 74±68 1.36 NS NS N: 29, 18, 5 46±78 56±66 109±28 0.64 NS NS N: 10, 20, 22 79±60 82±70++ 22±66 4.21 0.021 NS N: 25, 19, 8 45±81
want to be hugged N: 20, 20, 12 -4±66 41±70 68±88 2.97 NS NS N: 7, 28, 17 -1±39 25±87 52±69 1.08 NS NS N: 11, 30, 11 37±64 36±82 8±77 0.30 NS NS N: 29, 18, 5 29±82 34±78 21±57 0.71 NS NS N: 10, 20, 22 15±94 44±73 24±74 0.42 NS NS N: 25, 19, 8 35±94
want to hug N: 20, 20, 12 2±62 39±68 54±65 2.07 NS NS N: 7, 28, 17 20±71 21±66 44±69 0.36 NS NS N: 11, 30, 11 38±61 32±69 8±69 0.42 NS NS N: 29, 18, 5 31±73 28±64 16±51 0.74 NS NS N: 10, 20, 22 3±70 39±68 31±66 1.03 NS NS N: 25, 19, 8 31±79
Vital signs parameters ΔAUEC6
Systolic blood pressure, mmHg N: 44, 62, 18 98±42 93±41 115±44 1.65 NS NS N: 14, 61, 49 101±47 100±46 95±36 0.25 NS NS N: 29, 68, 27 89±43 101±43 100±38 0.68 NS NS N: 69, 45, 10 97±42 100±44 98±36 0.09 NS NS N: 22, 62, 40 92±43 102±46 95±34 0.16 NS NS N: 45, 60, 19 98±46
Diastolic blood pressure, mmHg N: 44, 62, 18 58±38 65±29 69±26 0.73 NS NS N: 14, 61, 49 69±38 62±34 63±28 0.25 NS NS N: 29, 68, 27 63±29 63±32 62±38 0.26 NS NS N: 69, 45, 10 68±31 54±34 70±28 3.46 0.034 NS N: 22, 62, 40 54±34 67±35 62±26 0.76 NS NS N: 45, 60, 19 63±31
Mean arterial pressure, mmHg N: 44, 62, 18 71±36 74±30 84±26 0.74 NS NS N: 14, 61, 49 79±34 75±34 74±28 0.21 NS NS N: 29, 68, 27 72±31 76±31 75±35 0.22 NS NS N: 69, 45, 10 78±31 69±33 80±27 1.57 NS NS N: 22, 62, 40 67±31 79±36 73±25 0.56 NS NS N: 45, 60, 19 75±32
Rate pressure product, mmHg/min N: 44, 62, 18 18572±8375 16677±9444 19299±8468 0.82 NS NS N: 14, 61, 49 18061±9152 17823±8399 17520±9676 0.04 NS NS N: 29, 68, 27 17749±8487 17854±9543 17399±8078 0.08 NS NS N: 69, 45, 10 17342±8481 18943±9287 14948±10432 1.17 NS NS N: 22, 62, 40 17977±9134 16643±8299 19280±9734 1.59 NS NS N: 45, 60, 19 17614±10248
Body temperature, °C N: 44, 62, 18 1.3±2.9 0.9±2.6 1.5±3.4 0.53 NS NS N: 14, 61, 49 -0.4±3.3 1.7±2.9* 0.9±2.4 3.53 0.032 NS N: 29, 68, 27 0.7±2.9 1.2±3.0 1.3±2.3 0.39 NS NS N: 69, 45, 10 0.8±2.9 1.6±2.7 1.0±2.9 1.16 NS NS N: 22, 62, 40 1.8±2.9 1.1±2.7 0.7±3.0 0.92 NS NS N: 45, 60, 19 0.8±2.6
Adjective Mood Rating Scale rating ΔAUEC5
well-being N: 44, 62, 18 14.9±23.3 11.4±22.8 9.5±30.3 0.39 NS NS N: 14, 61, 49 11.2±20.7 11.3±27.4 14.0±20.6 0.20 NS NS N: 29, 68, 27 12.5±24.2 11.1±20.6 15.2±31.6 0.23 NS NS N: 69, 45, 10 12.6±24.1 9.7±25.1 22.0±17.1 1.13 NS NS N: 22, 62, 40 14.6±17.5 17.1±21.7+ 3.7±28.4 4.23 0.017 NS N: 45, 60, 19 12.0±19.7
high mood N: 44, 62, 18 9.4±13.5 6.5±12.9 6.7±16.0 0.62 NS NS N: 14, 61, 49 7.5±11.3 7.3±15.2 8.0±12.2 0.04 NS NS N: 29, 68, 27 6.7±13.3 6.7±11.8 10.7±17.5 0.97 NS NS N: 69, 45, 10 7.6±14.1 6.4±13.2 12.5±10.9 0.81 NS NS N: 22, 62, 40 8.0±10.9 10.7±12.5++ 2.6±15.2 4.56 0.012 NS N: 45, 60, 19 8.1±11.6
fear/depression N: 44, 62, 18 -3.8±12.6 1.0±10.5 0.6±6.5 2.71 NS NS N: 14, 61, 49 -2.4±11.7 -0.4±12.3 -0.8±9.0 0.18 NS NS N: 29, 68, 27 -2.8±11.2 0.8±11.1 -2.6±10.3 2.08 NS NS N: 69, 45, 10 0.7±9.3 -2.5±13.4 -3.3±8.6 1.32 NS NS N: 22, 62, 40 1.2±8.2 -2.9±11.1 1.5±11.7 2.35 NS NS N: 45, 60, 19 1.9±9.4
dreaminess N: 44, 62, 18 9.2±9.2 8.6±10.7 6.3±12.4 0.64 NS NS N: 14, 61, 49 8.1±11.0 8.0±10.4 9.2±10.5 0.16 NS NS N: 29, 68, 27 8.8±11.2 9.3±10.7 6.0±8.8 0.62 NS NS N: 69, 45, 10 7.9±10.4 8.7±10.9 11.1±8.5 0.21 NS NS N: 22, 62, 40 8.7±12.4 10.5±9.5+ 5.1±10.1 3.13 0.047 NS N: 45, 60, 19 8.5±11.7
N, number of subjects; AUEC, area under the effect-time curve; SD, standard deviation; NS, not significant; D, values are change scores from placebo; ap value additionally corrected for multiple comparisons according to the Nyholt correction; * p < 0.05 compared to AA; + p < 0.05, ++ p < 0.01 compared to GG; # p < 0.05 compared to SS; ! p < 0.05 compared to LgSa/LgSa.  
 
Supplementary Table S2. Effects of polymorphisms in the serotonergic system  on the response to 125mg MDMA (mean±SD and statistics)
Visual Analog Scale rating ΔEmax TPH1 rs1800532 GG GT TT F p value p value
a TPH2 rs7305115 AA AG GG F p value p value
a 5HTR1A rs6295 CC CG GG F p value p value
a 5HTR1B rs6296 CC CG GG F p value p value
a 5HTR2A rs6313 AA AG GG F p value p value
a SLC6A4 5-HTTLPR LL
Any drug effect N: 44, 62, 18 81±19 73±26 74±26 1.30 NS NS N: 14, 61, 49 77±20 75±25 77±24 0.18 NS NS N: 29, 68, 27 79±20 79±23 66±27 2.92 NS NS N: 69, 45, 10 75±22 77±24 77±32 0.05 NS NS N: 22, 62, 40 69±24 80±23 73±24 1.92 NS NS N: 45, 60, 19 74±24
Good drug effect N: 44, 62, 18 81±23 72±29 72±28 1.52 NS NS N: 14, 61, 49 71±31 74±28 79±24 0.63 NS NS N: 29, 68, 27 77±23 77±28 71±29 0.56 NS NS N: 69, 45, 10 74±28 79±25 71±28 0.62 NS NS N: 22, 62, 40 76±23 81±26
+ 66±29 4.00 0.021 NS N: 45, 60, 19 70±27
Bad drug effect N: 44, 62, 18 14±23 21±29 14±19 1.22 NS NS N: 14, 61, 49 17±21 15±29 20±22 0.39 NS NS N: 29, 68, 27 25±24 17±26 10±24 2.49 NS NS N: 69, 45, 10 18±24 16±29 19±25 0.11 NS NS N: 22, 62, 40 13±20 17±27 22±25 0.95 NS NS N: 45, 60, 19 25±25
Drug liking N: 44, 62, 18 81±21 74±29 76±29 0.86 NS NS N: 14, 61, 49 69±35 76±27 81±23 1.28 NS NS N: 29, 68, 27 78±23 78±28 73±28 0.36 NS NS N: 69, 45, 10 77±27 79±25 70±30 0.49 NS NS N: 22, 62, 40 77±20 82±27 69±27 2.71 NS NS N: 45, 60, 19 72±27
Closeness to others N: 44, 62, 18 23±17 21±19 27±19 0.62 NS NS N: 14, 61, 49 19±20 22±17 25±19 0.85 NS NS N: 29, 68, 27 21±20 24±18 21±16 0.31 NS NS N: 69, 45, 10 22±18 23±19 28±18 0.52 NS NS N: 22, 62, 40 20±17 26±18 19±19 2.01 NS NS N: 45, 60, 19 19±20
High-mood N: 44, 62, 18 74±32 71±31 71±31 0.21 NS NS N: 14, 61, 49 72±29 69±34 75±28 0.57 NS NS N: 29, 68, 27 70±31 73±33 71±29 0.13 NS NS N: 69, 45, 10 70±31 76±31 66±39 0.59 NS NS N: 22, 62, 40 67±31 79±29 64±33 3.46 0.035 NS N: 45, 60, 19 68±32
Talkative N: 44, 62, 18 25±20 19±19 25±17 1.42 NS NS N: 14, 61, 49 18±23 21±19 24±17 0.79 NS NS N: 29, 68, 27 18±18 24±19 21±18 1.07 NS NS N: 69, 45, 10 21±19 22±20 24±16 0.09 NS NS N: 22, 62, 40 22±18 24±19 19±19 0.57 NS NS N: 45, 60, 19 22±18
Appetite N: 24, 42, 6 -7±33 -6±31 -15±22 0.22 NS NS N: 7, 33, 32 -3±32 -9±28 -6±34 0.14 NS NS N: 18, 38, 16 -13±37 -3±28 -10±30 0.78 NS NS N: 40, 27, 5 -4±31 -14±32 -2±22 0.95 NS NS N: 12, 42, 18 -6±29 -8±29 -6±37 0.06 NS NS N: 20, 41, 11 -8±31
Tired N: 41, 53, 15 21±32 18±33 23±31 0.19 NS NS N: 12, 54, 43 13±34 20±31 22±33 0.34 NS NS N: 26, 58, 25 23±34 22±31 11±33 1.33 NS NS N: 63, 39, 7 22±34 19±31 4±21 1.10 NS NS N: 20, 54, 35 22±27 20±34 18±33 0.11 NS NS N: 39, 54, 16 26±31
Fear N: 24, 42, 6 4±14 9±20 4±9 0.87 NS NS N: 7, 33, 32 -1±12 6±19 9±17 0.86 NS NS N: 18, 38, 16 6±9 9±23 3±8 0.82 NS NS N: 40, 27, 5 7±19 7±16 0±17 0.43 NS NS N: 12, 42, 18 0±4 6±13 14±27 2.73 NS NS N: 20, 41, 11 11±17
Happy N: 26, 40, 15 28±18 27±20 33±18 0.45 NS NS N: 12, 41, 28 27±21 28±18 29±20 0.05 NS NS N: 16, 48, 17 25±20 28±20 33±16 0.67 NS NS N: 44, 30, 7 28±19 28±20 37±17 0.76 NS NS N: 17, 34, 30 29±17 32±18 24±21 1.49 NS NS N: 33, 36, 12 26±21
Content N: 26, 40, 15 32±14 29±21 32±18 0.36 NS NS N: 12, 41, 28 27±22 30±17 32±19 0.29 NS NS N: 16, 48, 17 28±19 30±19 33±18 0.27 NS NS N: 44, 30, 7 31±18 28±19 37±17 0.71 NS NS N: 17, 34, 30 32±17 32±19 27±19 0.61 NS NS N: 33, 36, 12 28±19
Trust N: 20, 20, 12 23±18 23±23 25±26 0.02 NS NS N: 7, 28, 17 14±30 23±20 28±21 1.06 NS NS N: 11, 30, 11 20±24 23±21 27±24 0.29 NS NS N: 29, 18, 5 20±22 23±22 45±7 2.91 NS NS N: 10, 20, 22 35±17+ 28±20 14±23 4.15 0.022 NS N: 25, 19, 8 23±23
want to be hugged N: 20, 20, 12 11±19 19±20 24±20 1.64 NS NS N: 7, 28, 17 7±8 14±20 26±20 2.85 NS NS N: 11, 30, 11 14±19 18±21 19±19 0.17 NS NS N: 29, 18, 5 14±19 19±21 26±22 0.84 NS NS N: 10, 20, 22 17±19 23±20 12±20 1.65 NS NS N: 25, 19, 8 17±21
want to hug N: 20, 20, 12 14±19 19±19 23±19 0.99 NS NS N: 7, 28, 17 7±8 16±19 26±20 3.06 NS NS N: 11, 30, 11 14±19 18±20 22±16 0.42 NS NS N: 29, 18, 5 14±18 21±19 27±21 1.38 NS NS N: 10, 20, 22 20±17 23±19 12±20 1.71 NS NS N: 25, 19, 8 18±20
Vital signs parameters ΔEmax
Systolic blood pressure, mmHg N: 44, 62, 18 26±12 22±13 27±12 1.75 NS NS N: 14, 61, 49 22±13 25±14 23±11 0.73 NS NS N: 29, 68, 27 21±15 25±12 23±12 1.01 NS NS N: 69, 45, 10 23±13 27±12 22±10 1.41 NS NS N: 22, 62, 40 21±10 25±14 24±12 0.95 NS NS N: 45, 60, 19 23±13
Diastolic blood pressure, mmHg N: 44, 62, 18 14±11 14±9 15±9 0.10 NS NS N: 14, 61, 49 14±9 15±10 14±8 0.19 NS NS N: 29, 68, 27 16±9 14±10 13±9 0.59 NS NS N: 69, 45, 10 14±10 13±9 16±11 0.39 NS NS N: 22, 62, 40 14±14 14±9 14±7 0.01 NS NS N: 45, 60, 19 15±11
Mean arterial pressure, mmHg N: 44, 62, 18 18±10 17±10 19±9 0.25 NS NS N: 14, 61, 49 16±10 18±10 17±9 0.38 NS NS N: 29, 68, 27 18±10 18±10 16±9 0.37 NS NS N: 69, 45, 10 18±10 18±10 17±10 0.03 NS NS N: 22, 62, 40 17±12 18±10 18±8 0.21 NS NS N: 45, 60, 19 18±11
Rate pressure product, mmHg/min N: 44, 62, 18 5311±3048 4314±2906 4779±2783 1.48 NS NS N: 14, 61, 49 3757±2787 4786±2838 4952±3135 0.91 NS NS N: 29, 68, 27 4916±3052 4707±3032 4612±2729 0.08 NS NS N: 69, 45, 10 4513±2801 5306±3130 3702±2956 1.67 NS NS N: 22, 62, 40 4522±2610 4439±2772 5311±3360 1.13 NS NS N: 45, 60, 19 4525±2971
Body temperature, °C N: 44, 62, 18 0.3±0.5 0.2±0.5 0.4±0.5 1.24 NS NS N: 14, 61, 49 -0.1±0.6 0.3±0.5* 0.2±0.4 4.17 0.018 NS N: 29, 68, 27 0.2±0.6 0.2±0.5 0.3±0.4 0.58 NS NS N: 69, 45, 10 0.2±0.5 0.3±0.5 0.2±0.7 0.72 NS NS N: 22, 62, 40 0.3±0.5 0.2±0.6 0.2±0.5 0.24 NS NS N: 45, 60, 19 0.1±0.5
Adjective Mood Rating Scale rating ΔEmax
well-being N: 44, 62, 18 5.8±5.5 4.9±5.1 4.9±6.5 0.37 NS NS N: 14, 61, 49 3.4±4.3 5.3±6.0 5.5±4.9 0.92 NS NS N: 29, 68, 27 4.9±5.3 5.4±4.9 5.1±6.7 0.10 NS NS N: 69, 45, 10 5.2±5.1 4.7±5.9 7.7±4.9 1.30 NS NS N: 22, 62, 40 5.1±4.1 6.3±5.1+ 3.5±6.1 3.27 0.041 NS N: 45, 60, 19 5.4±5.0
high mood N: 44, 62, 18 3.5±3.1 2.7±3.1 2.9±3.7 0.75 NS NS N: 14, 61, 49 2.4±3.1 3.1±3.5 3.0±3.0 0.33 NS NS N: 29, 68, 27 2.6±3.2 3.0±3.0 3.4±3.9 0.41 NS NS N: 69, 45, 10 2.9±3.1 2.7±3.3 4.7±3.2 1.61 NS NS N: 22, 62, 40 2.8±2.7 3.7±3.0+ 2.0±3.6 3.82 0.025 NS N: 45, 60, 19 3.2±3.1
fear/depression N: 44, 62, 18 0.0±3.4 1.3±3.2 0.6±2.0 2.42 NS NS N: 14, 61, 49 -0.5±3.3 0.8±3.6 1.0±2.5 1.20 NS NS N: 29, 68, 27 0.2±3.2 1.3±3.3 0.0±2.7 2.15 NS NS N: 69, 45, 10 1.0±3.0 0.5±3.7 -0.2±1.9 0.80 NS NS N: 22, 62, 40 0.9±2.9 0.5±3.1 1.1±3.6 0.52 NS NS N: 45, 60, 19 1.6±3.0
dreaminess N: 44, 62, 18 3.3±2.6 3.1±3.5 2.5±3.2 0.43 NS NS N: 14, 61, 49 2.9±3.6 2.8±2.9 3.4±3.3 0.56 NS NS N: 29, 68, 27 3.2±3.3 3.4±3.2 2.1±2.7 1.83 NS NS N: 69, 45, 10 3.0±3.2 3.0±3.2 4.1±2.8 0.57 NS NS N: 22, 62, 40 2.9±3.8 3.9±3.0++ 2.0±2.7 4.55 0.012 NS N: 45, 60, 19 3.0±3.2
List of Complaints Δscore
acute, up to 6h, N N: 44, 62, 18 8.5±7.4 8.6±6.8 8.5±4.8 0.01 NS NS N: 14, 61, 49 7.4±7.1 8.4±6.7 9.0±6.8 0.31 NS NS N: 29, 68, 27 7.7±7.0 9.1±6.4 8.0±7.3 0.51 NS NS N: 69, 45, 10 8.2±6.8 9.4±6.5 7.0±7.5 0.71 NS NS N: 22, 62, 40 7.3±5.8 8.2±6.6 9.8±7.4 1.15 NS NS N: 45, 60, 19 9.7±7.1
subacute, up to 24h, N N: 44, 62, 18 5.1±5.6 4.7±5.3 3.7±5.4 0.43 NS NS N: 14, 61, 49 2.9±4.2 4.7±5.9 5.2±5.0 0.94 NS NS N: 29, 68, 27 5.7±5.0 4.5±5.8 4.1±4.8 0.63 NS NS N: 69, 45, 10 5.0±5.5 4.6±5.3 3.2±5.9 0.47 NS NS N: 22, 62, 40 3.9±5.4 4.6±5.0 5.3±6.1 0.52 NS NS N: 45, 60, 19 5.3±5.9




Supplementary Table S3. Effects of polymorphisms in the serotonergic system on the response to 125mg MDMA (mean±SD and statistics)
Visual Analog Scale rating ΔAUEC6 TPH1 rs1800532 GG GT TT F p value p value
a TPH2 rs7305115 AA AG GG F p value p valuea 5HTR1A rs6295 CC CG GG F p value p valuea 5HTR1B rs6296 CC CG GG F p value p valuea 5HTR2A rs6313 AA AG GG F p value p valuea SLC6A4 5-HTTLPR LL
Any drug effect N: 44, 62, 18 203±91 189±99 197±84 0.28 NS NS N: 14, 61, 49 205±75 192±99 197±92 0.12 NS NS N: 29, 68, 27 193±81 208±99 165±87 2.14 NS NS N: 69, 45, 10 190±92 199±98 214±88 0.34 NS NS N: 22, 62, 40 184±90 214±95 173±89 2.54 NS NS N: 45, 60, 19 210±107
Good drug effect N: 44, 62, 18 240±118 218±119 207±106 0.69 NS NS N: 14, 61, 49 218±107 230±128 221±106 0.11 NS NS N: 29, 68, 27 217±106 237±124 202±107 0.99 NS NS N: 69, 45, 10 218±119 232±119 232±95 0.22 NS NS N: 22, 62, 40 219±119 248±112 191±117 2.99 NS NS N: 45, 60, 19 223±124
Bad drug effect N: 44, 62, 18 15±46 23±46 16±28 0.56 NS NS N: 14, 61, 49 21±31 16±54 22±31 0.27 NS NS N: 29, 68, 27 27±38 23±41 3±53 2.69 NS NS N: 69, 45, 10 19±45 18±38 30±59 0.33 NS NS N: 22, 62, 40 17±46 19±41 20±48 0.03 NS NS N: 45, 60, 19 33±60
Drug liking N: 44, 62, 18 257±118 231±119 232±132 0.67 NS NS N: 14, 61, 49 228±116 249±131 234±108 0.30 NS NS N: 29, 68, 27 230±111 248±125 232±119 0.31 NS NS N: 69, 45, 10 234±123 253±120 226±100 0.43 NS NS N: 22, 62, 40 232±121 266±111 205±125 3.44 0.035 NS N: 45, 60, 19 239±130
Closeness to others N: 44, 62, 18 38±59 33±59 63±68 1.80 NS NS N: 14, 61, 49 18±65 36±61 48±58 1.48 NS NS N: 29, 68, 27 36±61 39±68 41±39 0.06 NS NS N: 69, 45, 10 40±63 41±57 22±61 0.44 NS NS N: 22, 62, 40 33±58 47±62 29±60 1.17 NS NS N: 45, 60, 19 40±69
High-mood N: 44, 62, 18 180±123 170±107 168±117 0.11 NS NS N: 14, 61, 49 167±103 170±123 178±105 0.09 NS NS N: 29, 68, 27 161±100 186±124 153±96 1.05 NS NS N: 69, 45, 10 173±117 176±110 159±113 0.10 NS NS N: 22, 62, 40 161±121 192±107 151±116 1.80 NS NS N: 45, 60, 19 186±126
Talkative N: 44, 62, 18 29±70 7±71 45±100 2.23 NS NS N: 14, 61, 49 3±87 17±81 29±67 0.74 NS NS N: 29, 68, 27 3±76 24±81 31±63 1.06 NS NS N: 69, 45, 10 23±78 24±65 -11±105 0.91 NS NS N: 22, 62, 40 25±73 19±79 20±74 0.04 NS NS N: 45, 60, 19 27±87
Appetite N: 24, 42, 6 -44±94 -10±75 -33±59 1.41 NS NS N: 7, 33, 32 6±66 -28±91 -25±74 0.51 NS NS N: 18, 38, 16 -31±80 -11±79 -43±88 1.02 NS NS N: 40, 27, 5 -8±54 -43±109 -40±75 1.61 NS NS N: 12, 42, 18 -23±54 -30±81 -7±97 0.53 NS NS N: 20, 41, 11 -15±82
Tired N: 41, 53, 15 29±100 35±85 20±69 0.19 NS NS N: 12, 54, 43 39±77 28±90 31±92 0.07 NS NS N: 26, 58, 25 41±90 41±85 -5±91 2.69 NS NS N: 63, 39, 7 36±81 28±103 0±73 0.52 NS NS N: 20, 54, 35 32±55 34±94 26±97 0.09 NS NS N: 39, 54, 16 36±90
Fear N: 24, 42, 6 3±12 10±33 1±2 0.64 NS NS N: 7, 33, 32 0±4 9±37 7±13 0.26 NS NS N: 18, 38, 16 3±5 11±36 1±3 1.07 NS NS N: 40, 27, 5 7±34 7±14 1±8 0.12 NS NS N: 12, 42, 18 -1±3 4±9 18±50 2.34 NS NS N: 20, 41, 11 9±16
Happy N: 26, 40, 15 61±62 56±86 77±57 0.43 NS NS N: 12, 41, 28 48±88 62±79 66±62 0.25 NS NS N: 16, 48, 17 62±85 59±80 68±42 0.09 NS NS N: 44, 30, 7 56±80 62±68 91±61 0.70 NS NS N: 17, 34, 30 68±71 74±64 44±85 1.41 NS NS N: 33, 36, 12 58±84
Content N: 26, 40, 15 70±60 67±90 73±48 0.05 NS NS N: 12, 41, 28 57±98 71±76 72±61 0.20 NS NS N: 16, 48, 17 73±90 65±78 76±43 0.15 NS NS N: 44, 30, 7 63±80 69±66 107±62 1.05 NS NS N: 17, 34, 30 73±75 85±64 49±82 2.04 NS NS N: 33, 36, 12 67±83
Trust N: 20, 20, 12 50±59 54±85 68±71 0.25 NS NS N: 7, 28, 17 18±95 56±68 71±65 1.43 NS NS N: 11, 30, 11 40±94 55±64 74±68 0.62 NS NS N: 29, 18, 5 46±78 56±66 109±28 1.69 NS NS N: 10, 20, 22 79±60 82±70
++ 22±66 5.02 0.010 NS N: 25, 19, 8 45±81
want to be hugged N: 20, 20, 12 -4±66
 41±70 68±88 3.98 0.025 NS N: 7, 28, 17 -1±39 25±87 52±69 1.34 NS NS N: 11, 30, 11 37±64 36±82 8±77 0.56 NS NS N: 29, 18, 5 29±82 34±78 21±57 0.05 NS NS N: 10, 20, 22 15±94 44±73 24±74 0.57 NS NS N: 25, 19, 8 35±94
want to hug N: 20, 20, 12 2±62 39±68 54±65 2.84 NS NS N: 7, 28, 17 20±71 21±66 44±69 0.70 NS NS N: 11, 30, 11 38±61 32±69 8±69 0.63 NS NS N: 29, 18, 5 31±73 28±64 16±51 0.10 NS NS N: 10, 20, 22 3±70 39±68 31±66 0.99 NS NS N: 25, 19, 8 31±79
Vital signs parameters ΔAUEC6
Systolic blood pressure, mmHg N: 44, 62, 18 98±42 93±41 115±44 1.97 NS NS N: 14, 61, 49 101±47 100±46 95±36 0.19 NS NS N: 29, 68, 27 89±43 101±43 100±38 0.92 NS NS N: 69, 45, 10 97±42 100±44 98±36 0.06 NS NS N: 22, 62, 40 92±43 102±46 95±34 0.54 NS NS N: 45, 60, 19 98±46
Diastolic blood pressure, mmHg N: 44, 62, 18 58±38 65±29 69±26 0.89 NS NS N: 14, 61, 49 69±38 62±34 63±28 0.27 NS NS N: 29, 68, 27 63±29 63±32 62±38 0.01 NS NS N: 69, 45, 10 68±31 54±34 70±28 2.68 NS NS N: 22, 62, 40 54±34 67±35 62±26 1.46 NS NS N: 45, 60, 19 63±31
Mean arterial pressure, mmHg N: 44, 62, 18 71±36 74±30 84±26 1.03 NS NS N: 14, 61, 49 79±34 75±34 74±28 0.18 NS NS N: 29, 68, 27 72±31 76±31 75±35 0.14 NS NS N: 69, 45, 10 78±31 69±33 80±27 1.02 NS NS N: 22, 62, 40 67±31 79±36 73±25 1.26 NS NS N: 45, 60, 19 75±32
Rate pressure product, mmHg/min N: 44, 62, 18 18572±8375 16677±9444 19299±8468 0.90 NS NS N: 14, 61, 49 18061±9152 17823±8399 17520±9676 0.03 NS NS N: 29, 68, 27 17749±8487 17854±9543 17399±8078 0.02 NS NS N: 69, 45, 10 17342±8481 18943±9287 14948±10432 0.96 NS NS N: 22, 62, 40 17977±9134 16643±8299 19280±9734 1.07 NS NS N: 45, 60, 19 17614±10248
Body temperature, °C N: 44, 62, 18 1.3±2.9 0.9±2.6 1.5±3.4 0.51 NS NS N: 14, 61, 49 -0.4±3.3 1.7±2.9* 0.9±2.4 3.59 0.031 NS N: 29, 68, 27 0.7±2.9 1.2±3.0 1.3±2.3 0.36 NS NS N: 69, 45, 10 0.8±2.9 1.6±2.7 1.0±2.9 1.07 NS NS N: 22, 62, 40 1.8±2.9 1.1±2.7 0.7±3.0 0.97 NS NS N: 45, 60, 19 0.8±2.6
Adjective Mood Rating Scale rating ΔAUEC5
well-being N: 44, 62, 18 14.9±23.3 11.4±22.8 9.5±30.3 0.41162987 NS NS N: 14, 61, 49 11.2±20.7 11.3±27.4 14.0±20.6 0.19299241 NS NS N: 29, 68, 27 12.5±24.2 11.1±20.6 15.2±31.6 0.28315767 NS NS N: 69, 45, 10 12.6±24.1 9.7±25.1 22.0±17.1 1.07540335 NS NS N: 22, 62, 40 14.6±17.5 17.1±21.7+ 3.7±28.4 4.11754622 0.019 NS N: 45, 60, 19 12.0±19.7
high mood N: 44, 62, 18 9.4±13.5 6.5±12.9 6.7±16.0 0.62143618 NS NS N: 14, 61, 49 7.5±11.3 7.3±15.2 8.0±12.2 0.03719787 NS NS N: 29, 68, 27 6.7±13.3 6.7±11.8 10.7±17.5 0.93884665 NS NS N: 69, 45, 10 7.6±14.1 6.4±13.2 12.5±10.9 0.81509688 NS NS N: 22, 62, 40 8.0±10.9 10.7±12.5++ 2.6±15.2 4.55269053 0.012 NS N: 45, 60, 19 8.1±11.6
fear/depression N: 44, 62, 18 -3.8±12.6 1.0±10.5 0.6±6.5 2.67714633 NS NS N: 14, 61, 49 -2.4±11.7 -0.4±12.3 -0.8±9.0 0.18956566 NS NS N: 29, 68, 27 -2.8±11.2 0.8±11.1 -2.6±10.3 1.61655088 NS NS N: 69, 45, 10 0.7±9.3 -2.5±13.4 -3.3±8.6 1.46198903 NS NS N: 22, 62, 40 1.2±8.2 -2.9±11.1 1.5±11.7 2.51681099 NS NS N: 45, 60, 19 1.9±9.4
dreaminess N: 44, 62, 18 9.2±9.2 8.6±10.7 6.3±12.4 0.49383894 NS NS N: 14, 61, 49 8.1±11.0 8.0±10.4 9.2±10.5 0.18410361 NS NS N: 29, 68, 27 8.8±11.2 9.3±10.7 6.0±8.8 0.9582068 NS NS N: 69, 45, 10 7.9±10.4 8.7±10.9 11.1±8.5 0.41381799 NS NS N: 22, 62, 40 8.7±12.4 10.5±9.5+ 5.1±10.1 3.4603432 0.035 NS N: 45, 60, 19 8.5±11.7
N, number of subjects; AUEC, area under the effect-time curve; SD, standard deviation; NS, not significant; D, values are change scores from placebo; ap value additionally corrected for multiple comparisons according to the Nyholt correction;  p < 0.05 compared to TT; * p < 0.05 compared to AA; + p < 0.05, ++ p < 0.01 compared to GG;  p < 0.05 compared to SS;  p < 0.05 compared to LgSa/LgSa.  
